As Medexus Pharmaceuticals prepares to report its fiscal Q4 2026 results, investors are keenly interested in whether the company can continue its trend of exceeding earnings expectations.
Scheduled for after market close on August 10, 2026, Medexus Pharmaceuticals Inc (MDP.TO) is set to release its earnings for the quarter ending June 30, 2026. With a consensus EPS estimate of 0.11, the upcoming report will be closely scrutinized given the company's recent performance history, which includes three earnings beats in the last four quarters.
Recent earnings trend
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
+0.80%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 34.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+34.6% Upside
Current Price
C$5.06
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.5%
Annualized
90-Day Vol
42.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.05
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.37 | C$4.53 โ C$6.37 |
| 60 trading days | C$5.70 | C$4.48 โ C$7.26 |
| 90 trading days | C$6.05 | C$4.50 โ C$8.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-10 | โ | 0.1100 | โ |
| 2026-03-31 | 2026-06-25 | -0.1135 | 0.0100 | -1235.0% |
| 2025-12-31 | 2026-02-11 | 0.0034 | -0.0400 | +108.5% |
| 2025-09-30 | 2025-11-12 | -0.0100 | -0.0700 | +85.7% |
| 2025-06-30 | 2025-08-12 | 0.0100 | -0.0800 | +112.5% |
| 2025-03-31 | 2025-06-26 | -0.0259 | -0.1300 | +80.1% |
Advertisement
Investor takeaway: Investors should watch for Medexus's ability to maintain momentum, especially considering its strong product-level performance with GRAFAPEX. The potential for significant EPS growth of 245.3% year-over-year could influence market sentiment and share price movements.
EPS Estimate of 0.11, with a Year-Over-Year Growth Projection of 245.3%
The anticipated EPS growth reflects a significant turnaround from the prior year, indicating strong operational improvements and potential for enhanced profitability, but also raises expectations for the upcoming report.
Bull case
If Medexus can meet or exceed the EPS estimate of 0.11, it would boost investor confidence and could lead to a positive re-rating of the stock. The company has shown resilience, with strong product performance and a bullish analyst target of C$6.81, suggesting substantial upside.
Bear case
On the other hand, if Medexus falls short of expectations, especially after a recent EPS revision downwards from 0.13 to 0.10, it could trigger a negative reaction in the stock. Investors may also be cautious due to the company's recent history of volatility in earnings surprises.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
